Pfenex Inc., of San Diego, said its partner, Alvogen Inc., entered exclusive commercialization agreements for PF-708 to treat osteoporosis in patients at high risk of fracture with Pharmbio Korea, Jamp Pharma in Canada and Kamada Ltd. in Israel. Under the agreement, Pfenex is eligible to receive milestone payments and a percentage of net sales or transfer price.